ATE517122T1 - Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren - Google Patents

Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren

Info

Publication number
ATE517122T1
ATE517122T1 AT07012168T AT07012168T ATE517122T1 AT E517122 T1 ATE517122 T1 AT E517122T1 AT 07012168 T AT07012168 T AT 07012168T AT 07012168 T AT07012168 T AT 07012168T AT E517122 T1 ATE517122 T1 AT E517122T1
Authority
AT
Austria
Prior art keywords
nucleic acid
expression vectors
corresponding expression
modified cea
cea nucleic
Prior art date
Application number
AT07012168T
Other languages
English (en)
Inventor
Beni Rovinski
Linong Zhang
Mark Parrington
Linda R Gritz
Patricia Greenhalgh
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE517122T1 publication Critical patent/ATE517122T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
AT07012168T 2002-04-09 2003-04-09 Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren ATE517122T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37097202P 2002-04-09 2002-04-09

Publications (1)

Publication Number Publication Date
ATE517122T1 true ATE517122T1 (de) 2011-08-15

Family

ID=35134558

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07012168T ATE517122T1 (de) 2002-04-09 2003-04-09 Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
AT03719662T ATE369895T1 (de) 2002-04-09 2003-04-09 Modifizierte cea nucleinsäure und expressionsvektoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03719662T ATE369895T1 (de) 2002-04-09 2003-04-09 Modifizierte cea nucleinsäure und expressionsvektoren

Country Status (10)

Country Link
US (1) US7786278B2 (de)
EP (2) EP1496939B1 (de)
CN (1) CN1658899B (de)
AT (2) ATE517122T1 (de)
AU (1) AU2003223527B2 (de)
CY (1) CY1109926T1 (de)
DE (1) DE60315628T2 (de)
ES (1) ES2290449T3 (de)
PT (1) PT1496939E (de)
WO (1) WO2003085087A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756038B1 (en) * 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US20070048860A1 (en) * 1997-10-10 2007-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Carcinoembryonic antigen (CEA) peptides
DE60315628T2 (de) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto Modifizierte cea nucleinsäure und expressionsvektoren
TWI340168B (en) * 2003-05-07 2011-04-11 Tosoh Corp Method of detecting micrometastasis
ATE506444T1 (de) 2003-10-08 2011-05-15 Sanofi Pasteur Ltd Modifizierter cea/b7-vektor
JP5285855B2 (ja) * 2003-11-12 2013-09-11 アメリカ合衆国 膵癌を処置および予防するためのカスタムベクター
EP1694364B1 (de) 2003-11-12 2014-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services System zur behandlung und prävention von brustkrebs
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
EP3061462B1 (de) 2007-07-02 2019-02-27 Etubics Corporation Verfahren und zusammensetzungen zur erzeugung eines adenovirusvektors zur verwendung mit mehreren impfungen
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
CA2974237C (en) 2015-01-09 2021-07-20 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5378457A (en) 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4882278A (en) 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
US4923808A (en) 1985-03-12 1990-05-08 Genentech, Inc. Method for identifying mutants secreting high levels of heterologous proteins
US5141742A (en) 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US5122599A (en) 1986-08-13 1992-06-16 Molecular Diagnostics, Inc. CDNAS coding for members of the carcinoembryonic antigen family
US6013772A (en) 1986-08-13 2000-01-11 Bayer Corporation Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
US5274087A (en) 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
EP0347425B1 (de) 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Rekombinant-mykobakterielle impfstoffe
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US6699475B1 (en) 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
DE68922757T2 (de) 1988-01-29 1995-11-16 Lilly Co Eli Vektoren, Zusammensetzungen und Verfahren zur Expression von einem menschlichen Adevoharzimomantigen.
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990010693A1 (en) 1989-03-08 1990-09-20 Health Research, Inc. Recombinant poxvirus host selection system
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
WO1991011194A1 (en) 1990-01-24 1991-08-08 Biogen, Inc. Lfa-3 as a vaccine adjuvant
US5204243A (en) 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
CA2076753A1 (en) 1990-02-26 1991-08-27 Anthony J. Radford Shuttle plasmid for escherichia coli and mycobacteria
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0546073B1 (de) 1990-08-29 1997-09-10 GenPharm International, Inc. Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
CA2081028C (en) 1991-03-12 1999-12-14 Barbara P. Wallner Cd2 binding domain of lymphocyte function associated antigen 3
DK0584266T3 (da) 1991-05-06 2003-12-29 Us Gov Health & Human Serv Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
WO1992021376A1 (en) 1991-06-06 1992-12-10 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
EP0672116B1 (de) 1992-07-06 2003-06-04 President And Fellows Of Harvard College Deletionsmutanten als impfstoffe gegen cholera
US5462871A (en) 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
AU668772B2 (en) 1992-08-31 1996-05-16 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by HLA-A1, and uses thereof
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
AU683454B2 (en) 1993-02-22 1997-11-13 General Hospital Corporation, The Heterologous antigens in live cell vaccine strains
AU6816194A (en) 1993-04-20 1994-11-08 Robinson, William S. Methods and materials for treatment of individuals infected with intracellular infectious agents
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US5858776A (en) 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US5585461A (en) 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5686068A (en) 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5851523A (en) 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5554506A (en) 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
EP0789774A2 (de) 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Erhöhte immunantwort durch einführen von einem zytokingen und/oder einem kostimulierenden b7-gen in einem rekombinanten virus-exprimierenden system
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
ES2154738T3 (es) 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0857176A1 (de) 1995-10-25 1998-08-12 Centocor B.V. VON HUMANEM EPITHELANTIGEN Ep-CAM ABGELEITETE PEPTIDE UND IHRE ANWENDUNG
EP0866721A4 (de) 1995-12-08 2003-06-04 Univ Alabama Birmingham Res Fo Adenovirale zielvektoren
FR2746110B1 (fr) 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
AU731860B2 (en) 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
AU718945B2 (en) 1996-07-25 2000-05-04 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
WO1998029556A1 (en) 1996-12-31 1998-07-09 The Wistar Institute Recombinant adenoviral vector expressing antigens associated with colorectal tumors
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
NZ500740A (en) 1997-05-13 2001-02-23 Univ North Carolina Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
EP1017797B1 (de) 1997-09-24 2005-06-22 The Regents Of The University Of California Nicht-primaten lentivirale vektoren und verpackungssysteme
US7084239B1 (en) 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US20070048860A1 (en) 1997-10-10 2007-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Carcinoembryonic antigen (CEA) peptides
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
KR100743894B1 (ko) 1998-02-27 2007-07-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 백신, 면역치료제 및 그의 이용 방법
EP1071333A4 (de) 1998-03-20 2005-02-23 Genzyme Corp Induktion von immunität gegen tumor-autoantigene
US6171855B1 (en) 1998-05-28 2001-01-09 The Regents Of The University Of Michigan Vectors
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
CA2721011A1 (en) * 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001049317A2 (en) 2000-01-05 2001-07-12 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
CN1314472A (zh) 2000-03-22 2001-09-26 上海博德基因开发有限公司 一种新的多肽——人酪氨酸酶12和编码这种多肽的多核苷酸
CN1314474A (zh) 2000-03-22 2001-09-26 上海博德基因开发有限公司 一种新的多肽——人酪氨酸酶16和编码这种多肽的多核苷酸
WO2001093897A2 (en) 2000-06-02 2001-12-13 Entremed, Inc. Angiostatin and endostatin binding proteins and methods of use
US20040091995A1 (en) 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
US20030113919A1 (en) 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
WO2003080800A2 (en) 2002-03-20 2003-10-02 Aventis Pasteur, Inc. Prevention and treatment of disease using angiogenesis-and/or tumor antigens
DE60315628T2 (de) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto Modifizierte cea nucleinsäure und expressionsvektoren

Also Published As

Publication number Publication date
AU2003223527A1 (en) 2003-10-20
EP1864691A1 (de) 2007-12-12
EP1496939A4 (de) 2005-11-23
WO2003085087A2 (en) 2003-10-16
EP1864691B1 (de) 2011-07-20
WO2003085087A3 (en) 2003-11-27
DE60315628D1 (de) 2007-09-27
ATE369895T1 (de) 2007-09-15
PT1496939E (pt) 2007-11-22
ES2290449T3 (es) 2008-02-16
US7786278B2 (en) 2010-08-31
EP1496939B1 (de) 2007-08-15
US20070082391A1 (en) 2007-04-12
AU2003223527B2 (en) 2009-01-15
DE60315628T2 (de) 2008-06-05
WO2003085087A8 (en) 2005-09-15
CN1658899B (zh) 2013-01-02
CY1109926T1 (el) 2014-09-10
CN1658899A (zh) 2005-08-24
EP1496939A2 (de) 2005-01-19

Similar Documents

Publication Publication Date Title
CY1109926T1 (el) Τροποποιημενο νουκλεϊκο οξυ και φορεις εκφρασης cea
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
DE69707985D1 (de) Kodierende sequenzen des menschlichen brca1-gens
DE69924826T8 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
ATE437232T1 (de) Rekombinanter adenoviren-vektor und verfahren zur verwendung
DK1516932T3 (da) Koppevirus med målrettet infektionsspecificitet
DE60038567D1 (de) Modifiziertes gp100 und dessen verwendung
DE60043125D1 (de) Zusammensetzungen und Verfahren für die Tumor-Behandlung
DK1536006T3 (da) Cancerantigener og anvendelse deraf
EP1100815A4 (de) Von protease typ ii spaltbares peptid
DE69941273D1 (de) Zusammenstellung und Verfahren zur Diagnose von Tumoren
NO20032818D0 (no) Polypeptider
IL174466A0 (en) Modified cda/b7 vector
WO2005068640A3 (en) Modified ksa and uses thereof
WO2003095642A3 (en) Polyepitopes and mini-genes for cancer treatment
ATE304593T1 (de) Menschliches gen und protein eines magenkrebs- antigens
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
ATE211912T1 (de) Umkehrung des phänotyps transformierter zellen durch transkriptionsfaktor irf-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties